文献速递乳腺癌

70基因MammaPrint检测预测NRG Oncology/NSABP B-42试验中延长来曲唑治疗获益的效用

Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial.
PubMed 文献 · J Clin Oncol · 2024-07-24

在NSABP B-42试验的1,866例早期乳腺癌患者中评估MammaPrint(MP)预测延长来曲唑治疗(ELT)获益的能力。主要终点远处复发(DR)的预测假设未获证实(交互P=0.38),但MP低危组10年DR获益3.7%显著(HR 0.43,95%CI 0.25-0.74;P=0.002),MP高危组获益2.4%不显著。

要点

  • MP低危组10年DR获益3.7%显著(HR 0.43),MP高危组获益2.4%不显著。
  • MP对DR的预测能力主要假设未获证实,交互P=0.38。
  • 探索性分析中MP低非超低危组10年DR、DFS、BCFI获益均显著。

核心结论

  • MP对DR预测能力的主要假设未获证实,但次要结局显示MP可预测ELT反应并识别从ELT获益的早期激素受体阳性乳腺癌(MP低危)患者。

研究设计与样本

  • 在NSABP B-42试验的1,866例随机接受ELT或安慰剂的患者中检测MP。
  • 主要终点为DR,次要终点为DFS和BCFI。
  • 肿瘤分为MP高危(MP-HR)或低危(MP-LR),MP-LR进一步分为超低危(MP-UL)和低非超低危(MP-LNUL)。

主要发现

  • ELT对DR的获益在MP-HR与MP-LR间无统计学显著差异(交互P=0.38)。
  • MP-LR组(n=1,160)10年DR获益3.7%显著(HR 0.43,95%CI 0.25-0.74;P=0.002),MP-HR组(n=706)获益2.4%不显著(HR 0.65,95%CI 0.34-1.24;P=0.19)。
  • MP-LR组10年DFS获益7.8%、BCFI获益7.0%显著,MP-HR组不显著(交互DFS P=0.015,BCFI P=0.006)。
  • 探索性分析中MP-LNUL组(n=908)10年DR获益4.0%、DFS获益9.5%、BCFI获益7.9%均显著;MP-UL组(n=252)DR获益3%、DFS获益1.8%、BCFI获益4.1%均不显著。

临床怎么用

  • 作者认为这些数据可能对超越临床风险评估选择延长内分泌治疗患者具有重要临床意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: MammaPrint (MP) determines distant metastatic risk and may improve patient selection for extended endocrine therapy (EET). This study examined MP in predicting extended letrozole therapy (ELT) benefit in patients with early-stage breast cancer (BC) from the NSABP B-42 trial. PATIENTS AND METHODS: MP was tested in 1,866 patients randomly assigned to receive ELT or placebo. The primary end point was distant recurrence (DR). Secondary end points were disease-free survival (DFS) and BC-free interval (BCFI). Tumors were classified as MP high risk (MP-HR) or low risk (MP-LR). MP-LR tumors were further classified as ultralow risk (MP-UL) or low non-ultralow risk (MP-LNUL). RESULTS: There was no statistically significant difference in ELT benefit on DR between MP-HR and MP-LR (interaction P = .38). MP-LR tumors (n = 1,160) exhibited a statistically significant 10-year benefit of 3.7% for DR (hazard ratio [HR], 0.43 [95% CI, 0.25 to 0.74]; P = .002), whereas MP-HR tumors (n = 706) exhibited a nonsignificant 2.4% benefit (HR, 0.65 [95% CI, 0.34 to 1.24]; P = .19). The 10-year ELT benefit was significant for DFS (7.8%) and BCFI (7.0%) for MP-LR tumors, whereas MP-HR tumors did not significantly benefit (interaction DFS: P = .015, BCFI: P = .006). In exploratory analysis, the 10-year ELT benefit was significant and more pronounced in MP-LNUL (n = 908) tumors: 4.0% for DR, 9.5% for DFS, and 7.9% for BCFI; the benefit in MP-UL (n = 252) tumors was not significant: 3% for DR, 1.8% for DFS, and 4.1% for BCFI. CONCLUSION: The primary hypothesis of predictive ability of MP on DR was not confirmed. However, the secondary outcomes demonstrated MP was predictive of ELT response and identified a subset of patients with early-stage hormone receptor-positive BC (MP-LR) with improved outcomes from ELT. These data could have important clinical implications in patient selection beyond clinical risk assessment for EET.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rastogi P, Bandos H, Lucas PC, et al. Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial. J Clin Oncol. 2024. PMID: 39047219. doi:10.1200/JCO.23.01995

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。